IP Library Granted Patent US 10,550,066
Granted Patent B2
US 10,550,066 · App. 15/945,408 · Granted Feb 4, 2020

Substituted aromatic compounds and related method for the treatment of fibrosis

Inventors: Boulos Zacharie (Laval, CA); Shaun Abbott (Pointe-Claire, CA); Lyne Gagnon (Laval, CA); Pierre Laurin (Ville Mont-Royal, CA); Brigitte Grouix (Montreal, CA)
Assignee: PROMETIC PHARMA SMT LIMITED
C07C53/134A61K31/192C07C57/30C07C57/58C07C59/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,550,066
App. No.
15/945,408
Granted
Feb 4, 2020
Kind
B2
Abstract

The present invention relates to compounds of: or a pharmaceutically acceptable salt thereof, wherein A is C 5 alkyl, C 6 alkyl, C 5 alkenyl, C 6 alkenyl, C(O)—(CH 2 ) n —CH 3 or CH(OH)—(CH 2 ) n —CH 3 wherein n is 3 or 4; R 1 is H, F or OH; R 2 is C 5 alkyl, C 6 alkyl, C 5 alkenyl, C 6 alkenyl, C(O)—(CH 2 ) n —CH 3 or CH(OH)—(CH 2 ) n —CH 3 wherein n is 3 or 4; R 3 is H, F, OH or CH 2 Ph; R 4 is H, For OH; Q is 1) (CH 2 ) m C(O)OH wherein m is 1 or 2, 2) CH(CH 3 )C(O)OH, 3) C(CH 3 ) 2 C(O)OH, 4) CH(F)—C(O)OH, 5) CF 2 —C(O)OH, or 6) C(O)—C(O)OH; and compositions comprising the same and the method using the same for the prevention or treatment of various fibrotic diseases and conditions in subjects, including pulmonary fibrosis, liver fibrosis, skin fibrosis, renal fibrosis, pancreas fibrosis, systemic sclerosis, cardiac fibrosis or macular degeneration.

Claims (21)

1. A pharmaceutically acceptable salt of a compound represented by the formula:

wherein

A is straight C 5 alkyl, straight C 6 alkyl, C 5 alkenyl, C 6 alkenyl, C(O)—(CH 2 ) n —CH 3 or CH(OH)—(CH 2 ) n —CH 3 wherein n is 3 or 4;

R 1 is H, F or OH;

R 2 is straight C 5 alkyl, straight C 6 alkyl, C 5 alkenyl, C 6 alkenyl, C(O)—(CH 2 ) n —CH 3 or CH(OH)—(CH 2 ) n —CH 3 wherein n is 3 or 4;

R 3 is H, F, OH or CH 2 Ph;

R 4 is H, F or OH;

Q is

1) (CH 2 ) m C(O)OH wherein m is 1 or 2,

2) CH(CH 3 )C(O)OH,

3) C(CH 3 ) 2 C(O)OH,

4) CH(F)—C(O)OH,

5) CF 2 —C(O)OH, or

6) C(O)—C(O)OH.

2. The compound according to claim 1 , wherein the pharmaceutically acceptable salt of said compound is sodium, potassium, lithium, ammonium, calcium, magnesium, manganese, zinc, iron, or copper.

3. The compound of claim 2 , wherein the pharmaceutically acceptable salt of said compound is sodium.

4. The compound according to claim 1 wherein said compound is one of the following compounds:

5. A compound that is a free acid form selected from 2-(3,5-dipentylphenyl) acetic acid, 2-(3,5-Dihexylphenyl)acetic acid, 2-(2-Hydroxy-3,5-dipentylphenyl)acetic acid, 2-(3,5-Dihexyl-2-hydroxyphenyl)acetic acid, 2-(4-Hydroxy-3,5-dipentylphenyl)acetic acid, 2-(3,5-Dihexyl-4-hydroxyphenyl)acetic acid, 2-(4-Fluoro-3,5-dihexylphenyl)acetic acid, and 2-(4-Fluoro-3,5-dipentylphenyl)acetic acid; or a pharmaceutically acceptable salt thereof.

6. The compound of claim 5 , which is 2-(3,5-dipentylphenyl) acetic acid or a pharmaceutically acceptable salt thereof.

7. The compound of claim 5 , wherein the pharmaceutically acceptable salt of said compound is sodium, potassium, lithium, ammonium, calcium, magnesium, manganese, zinc, iron, or copper.

8. The compound of claim 6 , wherein the pharmaceutically acceptable salt of 2-(3,5-dipentylphenyl) acetic acid is sodium 2-(3,5-dipentylphenyl) acetate.

Assignments (3)
CHANGE OF NAME Recorded Jan 31, 2020
From: PROMETIC PHARMA SMT LIMITED
To: LIMINAL BIOSCIENCES LIMITED
Reel/Frame 051766/0935 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2018
From: PROMETIC BIOSCIENCES INC.
To: PROMETIC PHARMA SMT LIMITED
Reel/Frame 045608/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2018
From: ZACHARIE, BOULOS; ABBOTT, SHAUN; GAGNON, LYNE; LAURIN, PIERRE; GROUIX, BRIGITTE
To: PROMETIC BIOSCIENCES INC.
Reel/Frame 045600/0348 →
Continuity (3)
Division 14776328
Provisional Application 61798269 · Mar 15, 2013
Related Publication 20180237374A1 · Aug 23, 2018